

DB-ALM Protocol n° 101 : Colony Forming Unit-Granulocyte/Macrophage (CFU-GM) Assay

Haematotoxicity, Systemic Toxicity

The haematotoxic potential of xenobiotics is determined by the evaluation of the inhibition of CFU-GM growth.

Objective & Application

TYPE OF TESTING	: screening, reduction, partial replacement
LEVEL OF ASSESSMENT	: toxic potency, hazard/risk assessment
PURPOSE OF TESTING	: classification and labelling

Context of Use:

The CFU-GM assay is used in a screening mode to predict chemical induced myelosuppression, one of the haematological parameters to be considered for the assessment of the haematotoxic potential of chemical compounds of various kinds. The assay shall find its application in addition to general screening purposes, first of all, during pre-clinical drug developments of antineoplastics and clinical therapy settings.

Applicability Domain:

After the conclusion of the ECVAM validation study, the standard operating procedure (SOP) enclosed within the **Technical Description** has been proposed by the Management Team of the study to be included as an integral part of the test batteries of toxicological methods required by regulators for the approval of pharmaceuticals, industrial chemicals and food additives (Anon., 2000; Gribaldo *et al.*, 1996; Pessina *et al.*, 2001, 2002 and 2003).

The ECVAM Scientific Advisory Committee (ESAC) unanimously endorsed the CFU-GM assay for predicting acute neutropenia in humans as a substitute to using a second species, such as the dog, for this purpose (ESAC, 2006, Pessina *et al.* 2001, 2003).

The predictive capacity for hematotoxicity of the CFU-GM assay was used further in the toxicity profiling of industrial chemicals with documented accidental exposure and human blood concentration data at acute poisoning (Cerrato *et al.*, 2009). In the course of the EU Integrated project ACuteTox (www.acutetox.eu) the assay was considered as one of the potential building blocks of non-animal testing strategies (Prieto *et al.*, 2013), which may provide information on diverse human health hazards, predictive of acute oral toxicity potential, for the purpose of EU CLP regulation (EU, 2008).

Résumé

Colony forming assays are employed to investigate the direct adverse effects of xenobiotics on the blood-forming system. Multipotential stem cells of this system, also called colony-forming units (CFU), give rise to progenitors already committed to differentiate into different lineages of mature blood cells depending on humoral growth factors and local cytokines in their particular microenvironment.

Conditions have been developed that support the *in vitro* formation of the colonies of red cells, granulocytes, macrophages etc. by the clonal growth and maturation of progenitor cells. Which type of haematopoietic colonies is formed depends on the provision of appropriate nutrients and growth factors added to the culture medium.

The procedure of the attached SOP describes the use of semi-solid media, which allow the clonal progeny of the precursors of granulocytes and/or macrophages: CFU-GM assay (Colony Forming Unit of Granulocytes and/or Macrophages).

This CFU-GM *in vitro* test detects the direct adverse effects of xenobiotics on the proliferative capacities of the progenitors and should be able to predict the exposure level of xenobiotics that would cause clinical neutropenia after onset acute exposure (Gribaldo *et al.*, 1996; Pessina *et al.*, 2000).

Experimental Description

Endpoint and Endpoint Measurement:

CELL PROLIFERATION: Inhibition of cell proliferation by colony scoring

Endpoint Value:

IC₉₀: Inhibition of cell proliferation; 90% inhibitory concentration values

Experimental System(s):

CORD BLOOD (human): Human Cord Blood Mono Nuclear Cells (Hu-CBMNC)

BONE MARROW (murine): Murine bone marrow Mono Nuclear Cells (MNC)

Basic Procedure

Haematopoietic progenitor cells

Murine bone marrow cells are collected from femura isolated from sacrificed mice. As human tissue, cord blood cells are used which are known to contain high numbers of primitive haemopoietic progenitor cells. Thus, cord blood mononuclear cells (CBMNC) are assumed to be a good alternative to human bone marrow haemopoietic stem cells for both research and clinical applications. The culture method is enclosed in the Technical Description.

CFU-GM assay summary

The methylcellulose culture media (MCM) is prepared and dispensed in round bottom tubes. The test compounds, the MCM and the cells are mixed, prior to plating the culture dishes. For each experiment there are: three linearity control dishes, two vehicle controls, and six for the drug-curve. The volumes of vehicle and drug stock is added to the methylcellulose tubes (see tables of the SOP). Then the mouse MNC or Hu-CBC cell suspensions are added to each tube and the cell-medium mixture is distributed into each of three Petri dishes.

The cell cultures are then exposed to the test compounds for 7 days at 37°C in air + 5% CO₂ under saturated humidity. Colonies are counted at the end of the 7 days incubation time (murine cells) and 14 days (human cells). CFU-GM colonies are scored by scanning the whole Petri dish by using an inverted microscope, following the criteria for colony counting.

Data Analysis/Prediction Model

The Prediction Model (PM) focuses on one clinical parameter of neutropenia: the depth of nadir (severity, the lowest post-treatment blood cell count). Animal data have shown that there is a clear relationship between the reduction in CFU-GM and the decrease of the absolute neutrophil count (ANC). The prediction of the acute xenobiotic exposure levels that would cause these maximum tolerated decreases in ANC is the goal of *in vitro* haematotoxicology (Erickson-Miller *et al.*, 1997; Parchment *et al.*, 1994).

For the purpose of the ECVAM's study " *In Vitro* tests for haematotoxicity: prevalidation and validation of Colony Forming Unit Granulocyte/Macrophage (CFU-GM) assays for predicting acute neutropenia" (1997 – 2000) the IC₉₀ (90% inhibitory concentration values) determined for each drug in human and murine were used to predict a human Maximum Tolerated Dose (MTD). Accurate prediction is defined as the prediction of human MTD that lies with 4-fold of the actual human value.

Example (from Pessina *et al.*, 2000):

Xenobiotic	IC ₉₀ ratio (Human: murine)	Murine MTD (mg/m ² /cycle)	Predicted Human MTD	Actual Human MTD (mg/m ² /cycle)	Successful Prediction (Yes/No)
Flavopiridol	0.41	100	41	50	yes

Test Compounds and Results Summary

Drugs (anti-neoplastics, anti-virals, anti-inflammatories, etc.); environmental contaminants (pesticides); food additives and contaminants (mycotoxins); industrial chemicals.

Discussion

Complete "prediction of neutropenia" for a xenobiotic from *in vitro* testing requires an accurate prediction for each parameter (Parchment and Murphy 1997, Parchment 1998). Currently there are three clinical prediction models for the depth of the neutrophil nadir published in the literature (Parchment *et al.*, 1993; Parchment and Murphy 1997; Parchment 1998; Parchment *et al.*, 1998). They differ in complexity, the amount of pharmacological information required to make predictions, and the accuracy of those predictions. In general, the more data intensive models provide the most accurate predictions.

However, the most generally useful model is the one that requires the least amount of specialized pharmacological information, since parameters like plasma clearance rate are often unavailable at the time permissible exposure limits are set.

The prediction model selected for evaluating in Phase I of the ECVAM study, "*In Vitro* tests for haematotoxicity: prevalidation and validation of Colony Forming Unit Granulocyte/Macrophage (CFU-GM) assays for predicting acute neutropenia" (1997 – 2000), generates an estimate of human Maximum Tolerated Dose by adjusting an animal MTD from registration toxicology (for example rat) for the intrinsic difference in drug tolerance between the experimental species and humans, and also for the differential sensitivity between CFU-GM from the animal species and the human. This model can be used without knowledge of pharmacokinetic differences across species. Nevertheless, this model should be capable of predicting human exposure levels within 4-fold of the actual (the inter-species variation in tolerated dose due to differences in clearance rates), and this is sufficient accuracy to contribute to setting permissible exposure limits. This simple model is the one that was evaluated during the performance phase of this validation study.

It is important to note that available models predict the human exposure that produces a neutrophil nadir severe enough to be associated with significant clinical risk of infection. Therefore, the predicted value is the maximum tolerated dose of an acute exposure. To set safe exposure levels, the PEL would be set at some dose level below the predicted MTD and the scale of the reduction is dependent upon the intended use, if any, of the xenobiotic. (Anon., 1998).

The Rationale of the Prediction Model

The goal of *in vitro* haematotoxicology is the prediction of the acute xenobiotic exposure levels that cause these maximum tolerated decreases in absolute neutrophil count (ANC). The prediction model tested in Phase I of the ECVAM prevalidation study has evolved from recent studies that sought to correlate *in vitro* and *in vivo* data (Parchment *et al.*, 1994; Erickson-Miller *et al.* 1997; Parchment and Murphy 1997; Deldar and Parchment 1997; Parchment 1998). Initial experience with pyrazoloacridine (PZA) proved the feasibility of predicting drug exposure levels that cause grade 3-4 neutropenia in humans from *in vitro* data (Parchment *et al.*, 1994).

Grade 4 neutropenia is to be considered dose-limiting toxicity, and its severity represents about 90% decrease in ANC for patients with normal marrow function, while Grade 3 is to be considered tolerable and represents 75% reduction. The prediction model is therefore highly dependent upon the correct selection of the degree of inhibition of the dose-limiting neutrophil progenitor. From the PZA study in humans (Parchment *et al.*, 1994), it was apparent that the drug exposure level that inhibits CFU-GM by 90% *in vitro* and decreases ANC by 90% *in vivo* were the same.

The importance of the IC₉₀ value has been confirmed by different studies (Erickson-Miller *et al.*, 1997; Parent-Massin and Parchment, 1998). All studies indicated that the normally used IC₅₀ does not predict clinically important levels of drug exposure in patients with adequate marrow function (Parchment *et al.*, 1994; Erickson-Miller *et al.*, 1997). In fact, the IC₅₀ may represent a loss of CFU-GM that causes no more than mild neutropenia after acute exposure.

Some *in vitro* studies have emphasized IC₇₀-IC₇₅ values, reflecting the clinical view that it is more important to predict exposure levels that result in grade 3 neutropenia, rather than grade 4 (Ghielmini *et al.*, 1997). The IC₇₀ may also be a useful endpoint in patients with mild neutropenia, because grade 4 neutropenia may result in these patients from a smaller decrease in ANC. However, determining the predictive IC endpoint for neutropenia might depend on the pretreatment ANC of the patient. A prospective or retrospective clinical trial will be required to determine the relative predictive value of the IC₉₀ versus the IC₇₀. For purposes of the ECVAM study, it was decided to use the IC₉₀ in the prediction model because most exposed individuals would likely not be pre-exposed to marrow toxicants like anticancer drugs.

Determining the predictive IC test parameter for neutropenia might depend on the pretreatment ANC of the patient. A prospective or retrospective clinical trial will be required to determine the relative predictive value of the IC₉₀ versus the IC₇₀. For purposes of the ECVAM prevalidation study, the authors decided to use the IC₉₀ in the prediction model because most exposed individuals would likely not be

pre-exposed to marrow toxicants like anticancer drugs (Anon., 1998).

Further developments

Following the ECVAM validation, different future applications of the CFU-GM assay were subsequently studied.

- The CFU-GM assay was transferred to a 96-well plate microassay to facilitate its application for its use as a screening test of new drugs (Pessina *et al.*, 2004).
- Later, the CFU-GM assay was applied to different bone marrow progenitors – megakaryocytes (called the human Colony Forming Unit-Megakaryocytes assay (CFU-Mk)). CFU-Mk assay protocol was successfully refined and optimised in an international study and a prediction model was defined to assess drug-induced thrombocytopenia (Pessina, Parent-Massin *et al.*, 2009).
- The CFU-GM assay, where murine bone marrow and human cord blood mononuclear cells were used, was adapted to the rat model. The Rat CFU-GM assay which incorporates the use of frozen cryopreserved rat bone marrow cells was refined and optimised for prediction of drug-induced haematotoxicity (Pessina, Bonomi *et al.*, 2009) and its intra-laboratory and inter-laboratory variability was successfully evaluated in an international study by Pessina *et al.* (2010) too.

The standardised protocols of CFU-GM assay for evaluation of potential drug myelotoxicity have been developed by Pessina and Bonomi (2007, 2010).

Some subsequent studies used exclusively the human umbilical cord mononuclear blood cells as a test system for predicting the potential myelotoxicity of a test compound, adopting the data analysis and prediction model accordingly. For the purpose of the ACuteTox project, for each xenobiotic tested, the values of IC₅₀, IC₇₀ and IC₉₀ were measured. If no significant effect was observed at any concentration tested, the experiment was reported as "no true effect". The CFU-GM assay results, together with the LOEC or EC_x values of other endpoints assessed in the project were used in the classification analysis for the prediction of EU CLP acute oral toxicity category (Prieto *et al.* 2013).

Note: for CFU-Mk and rat CFU-GM assays the definition of new DB-ALM Protocols is foreseen in the future.

Status

Known Laboratory Use:

The widespread use of this technique in the past is documented in Gribaldo *et al.* (1996).

Participation in Evaluation Studies:

The method has successfully been prevalidated and the conclusion of this study (January 1997 – July 1998) was that the assay provides adequate performance in terms of colony numbers, potential sensitivity and linearity. The prediction model accurately predicted the actual human MTD values for five of the six test substances.

Participation in Validation Studies:

On the basis of these first results, a further phase concluding the formal validation study was conducted and completed in 2000: "***In Vitro* tests for haematotoxicity: prevalidation and validation of Colony Forming Unit Granulocyte/Macrophage (CFU-GM) assays for predicting acute neutropenia**" (1997 – 2000). The Management Team of this ECVAM study has concluded that this validation stage, where an additional panel of 20 drugs were tested, confirmed the positive results obtained in the prevalidation phase (Anon., 2000; Pessina *et al.*, 2000, 2001 and 2003).

Furthermore, in 2006, the **ECVAM Scientific Advisory Committee (ESAC) unanimously endorsed the CFU-GM assay for predicting acute neutropenia in humans as a substitute to using a second species, such as the dog, for this purpose**. It should be noted that the test relies on the availability of mouse MTD data and is, therefore, not a full replacement method, but is intended to reduce the overall numbers of animals needed in toxicity testing. Performance standards for the assay should be developed to enable reasonable flexibility in the protocol used (ESAC, 2006; Pessina *et al.* 2001, 2003).

Contribution to prediction of acute toxicity

The CFU-GM assay with human mononuclear cord blood cells was among 11 methods selected from 53 candidate *in vitro* and *in silico* test methods after the Phase I of the **ACuteTox** EU intergrated project (in collaboration with EURL ECVAM). All methods were evaluated in terms of variability and combined

preliminary predictive capacity to classify chemicals into the EU CLP acute oral toxicity categories (EC No. 1272/2008; EU, 2008; Kinsner-Ovaskainen et al., 2013).

The reliability of the CFU-GM was further evaluated during the Phase II of the project with a defined set of 32 selected chemicals (Prieto et al., 2013).

Abbreviations and Definitions

ANC – absolute neutrophil count

CBMNC – cord blood mono nuclear cells

CFU-GM – colony forming unit-granulocyte/macrophage

ECVAM – European Centre for the Validation of Alternative Methods

ESAC – ECVAM Scientific Advisory Committee

IC₉₀ – 90% inhibitory concentration value

MCM – methylcellulose culture media

MTD – maximum tolerated dose

SOP – standard operating procedure

Last update: June 2011

PROCEDURE DETAILS, July 1998*

Colony Forming Unit-Granulocyte/Macrophage (CFU-GM) Assay DB-ALM Protocol n° 101

This protocol presents the standard operating procedure used in the ECVAM validation study: "In Vitro tests for haematotoxicity: prevalidation and validation of Colony Forming Unit Granulocyte/Macrophage (CFU-GM) assays for predicting acute neutropenia" concluded in 2000. The same protocol was used by the ACuteTox project partner, responsible for hematotoxicity profiling (CIEMAT, Spain).

* The accuracy of the SOP has been confirmed by the responsible laboratory in June 2011.

Contact Details

Prof. Augusto Pessina

Associated Professor

Department of Biomedical, Surgical and Dental Sciences, Cell Culture Laboratory

University of Milan

Via Pascal, 36

Milan 201333

Italy

email: augusto.pessina@unimi.it

telephone: 0039 02 50315072

fax: 0039 02 50315068

Materials and Preparations

Cell or Test System

- Murine hematopoietic progenitors
- Human hematopoietic progenitors

Equipment

Fixed Equipment

- Microbiological Safety Cabinet
- Centrifuge
- Vortex
- Incubator, 37°C, 5% CO₂, 95% relative humidity
- Certified Eppendorf pipet 5-40 µl, 40-200 µl, 200-1000 µl
- Hemocytometer (e.g. Bürker, Neubauer)
- Inverted microscope (20-25x magnification)
- Warm waterbath at 37°C
- Inverted microscope (20-25x magnification)
- Freezer -80°C
- Freezer -20°C
- Refrigerator +4°C
- Freezing container "Mr.Frosty" Nalgene, Cat. N° 5100

Consumables

- 70% ethyl alcohol
- Gauze tissue
- Surgical material: little pair of scissors, surgery tweezers
- Needle 23 or 25 Ga, 18 Ga, 19 Ga
- Antibiotics: penicillin 100 U/ml – streptomycin 100 µg/ml (Gibco, Ref. 15140)

- Iscove's Modified Dulbecco's medium 1X (IMDM) (Gibco, Ref. 21980)
- Fetal Bovine Serum (FBS) (Gibco, Ref. 10084)
- Dimethyl Sulfoxide (DMSO) (SIGMA Ref. D-5879 or D 2650)
- PBS Dulbecco's Phosphate Buffer Saline without Calcium and Magnesium (GIBCO Ref. 14190)
- Ficoll-Paque Research Grade Ref. 17-0840-02 (Pharmacia Biotech.)(Store at 4°C and protect from direct light)
- Anticoagulant suggested CPD (Citrate-Phosphate-Dextrose solution) SIGMA Ref. C7165 (use at ratio 1.4:10)
- 0.22 µm disposable filter
- Human Serum Albumin (HSA) for clinical applications (Sigma, Ref. A 1653 Fraction V or Fluka Ref. 05418 Fraction V 99%)
- Dextran T 40: Rheomacrodex 10 % (Dextran Mw 40,000)(Pharmacia Biotech.Ref. 17-0270-1)
- Dnase I: Rnase free, 10U/ml (Boeringher, Ref. 776785)
- Trypan Blue 0.4% (Sigma, Ref. T8154)
- Turk Solution (HBSS containing 2% acetic acid + 0.01% Methylene Blue, Sigma, Ref. M9140)
- Methylcellulose culture media (MCM)(Stem Cell Technologies, specifically prepared)
- HBSS (Hanks balanced salt solution)
- Cell strainer: 100 µm cell strainer (Falcon, Ref. 2360)
- Cryotubes : 2,2 ml, Nalgène, Ref. A 12 984 75 or 1,2 ml, Falcon Ref.4806
- Petridish Ø 150 mm, Ø 60 mm
- Petridish Ø 35 mm (Nunc, Ref. 153066)
- Grided petridish Ø 60 mm
- Disposable syringe 5 ml, 10 ml, 1ml B-D insulin syringe
- 15 ml round bottom tubes (Falcon, Ref. 2057)
- Tubes for density gradient : 15 ml conical tubes (Falcon, Ref. 2097)
- 50 ml tube (Falcon, Ref. 2070)
- Melting ice
- Sterile disposable pipettes

Media, Reagents, Sera, others

Incubator humidification test

1. Prepare three Petri dishes of Ø 60 mm (Area = 28.27 cm²) and fill each dish with 10 ml of distilled water (Vs = Starting Volume).
2. Put the dishes in the incubator in the centre of the middle plateau.
After 72h measure the volume of water in each dish (Vf = Final Volume)
- 3.

$$ER(\mu\text{l} \times \text{h}^{-1} \times \text{cm}^{-2}) = \frac{V_s - V_f}{h \times a} = \frac{V_{72}}{2,035}$$

Calculate the Evaporation Rate (ER) of each one as follow

4. Calculate the mean \pm S.D. of the triplicate.

E.R. Values (ranges):

1.1 – 1.7	Very Good
1.7 – 2.1	Good
2.1 – 2.7	Acceptable
2.7 – 3.0	Poor
> 3.0	Unacceptable

Preparations

Media and Endpoint Assay Solutions

Methylcellulose culture media (MCM)

Type A: formulation from Stem Cell Technologies, Vancouver, Canada

- 1 % Methylcellulose in IMDM
- 30% Fetal Bovine Serum
- 1% Bovine Serum Albumine
- 2 mM L- glutamine
- 10 ng/ml GM-CSF*

* Depending on the experimental system: murine or human recombinant cytokines

Preparation of methylcellulose stocks

Thaw bottles of methylcellulose culture media (MCM) overnight at +4°C. Homogenize the MCM by inverting the bottle several times. With a 10 ml syringe and 18 Ga needle, dispense all of the MCM in the bottle into 4 ml aliquots in 15 ml round bottom tubes.

The precision in dispensing MCM represents a critical point in order to obtain the correct final concentration of methylcellulose and toxicant at later steps! If the medium runs along the tube wall, centrifuge the tube 140 X g, 30 sec to move it to the bottom. Dispense exactly 4 ml of MCM into a tared tube.

Aliquots must be stored at –20°C. Individual tubes can then be thawed and used as needed.

Method

Test System Procurement

Source of murine hematopoietic progenitors

For murine model bone marrow cells are used, collected from male BDF/1 (C57Bl/6 x DBA-2) mice, 8-12 weeks old. Three mice per experiment are used and all the procedures are performed in rigorous sterile conditions by using sterile reagents and materials and operating in a Microbiological Safety Cabinet. Keep the cells at + 4 °C (melting ice).

Isolation of murine bone marrow cells (mu-BMC)

1. Sacrifice the animals by cervical dislocation (without anaesthesia). After the animals have been killed, proceed as soon as possible. Wash the mice thoroughly with 70 % ethyl alcohol and leave the animal for 1-2 minutes entwined into a gauze alcohol imbued.
2. Remove the skin of the legs and isolate the intact femura by cutting the muscle ligaments using a little pair of scissors and tweezers in order to clean well the bones.
3. Put the six femura in a 150 mm petri dish containing 10 ml Iscove's Modified Dulbecco's medium (IMDM) supplemented with antibiotics (Penicillin 100 U/ml - Streptomycin 100 µg/ml) and maintain them at + 4°C on ice.
4. Clean the knee from the articular cartilage and cut both ends from the femura just below the head.
5. Hold the femur shaft with surgery tweezers, insert a 23 - 25 Ga needle mounted on a 5 ml syringe into the "knee end" and flush marrow out of the end with IMDM without antibiotics. Use 2 x 1.5 ml flushing per femur. Collect the bone marrow cells from all femura in a single 15 ml round bottom or 50 ml tube. Calculate 3 ml for each femur.
6. Disperse the BMCs with the syringe by repeated flushing (5 times) and transfer the cell suspension with the syringe into a 50 ml sterile tube by filtering them through a 100 µm disposable cell strainer.
7. Wash the cells at 400 x g, 10 minutes, discard the supernatant and resuspend the pellet in Iscove's medium (calculate 1 ml for each femur) supplemented with 30% FBS without antibiotics.
8. Dilute 50 ml of cells plus 450 ml of HBSS containing 0.04% Trypan Blue and evaluate the percentage of cell viability immediately after making the suspension in a haemocytometer (e.g.: Bürker, Neubauer, etc.). Thereafter count the cells in the same way by using 10 ml of cells plus 90 ml of Turk Solution.

9. Adjust the suspension at 1.5×10^6 viable nucleated cells/ml (viability must be > than 95%), then dilute the cell suspension according to the cell densities to use as specified in the experimental design (see table 1).

Table 1: Example of cell dilution procedure for murine bone marrow cells.

Starting cell suspension: 1.5×10^6 /ml

Cell dilution	Tube	n°cells/dish (*)	Dilution for preparing 1 ml of cell suspension	
			Starting cells suspension (1.5×10^6 /ml)	IMDM+FBS 30%
A	CTRL 1	2,500	0.025 ml	0.975 ml
B	CTRL 3, D0® D8	40,000	0.391 ml	0.609 ml

(*) Cell density obtained if 0.3 ml of each dilution is added to the corresponding tube.

Note: The suspension must be constituted of single cells. If cell aggregates are present, they must be dispersed by gentle pipetting before counting!

Source of human haematopoietic progenitors

The sources of haematopoietic cells used in the described procedure are cryopreserved human cord blood mononuclear cells (huCBMNC). A minimum of two frozen aliquots of CBCs from a single donor is required to complete the screening Phase and the IC Determination Phase of testing.

Collection of human umbilical cord blood cells (huCBC)

1. Add 7 ml of CPD in 50 ml tube (ratio 1.4 CPD : 10 cord blood).
2. Place the tube at room temperature.
3. Collect 43ml of cord blood after normal delivery in sterile conditions if possible.
4. Keep the sample at room temperature.
5. The cord blood cells has to be cryopreserved or cultivated at least 24 after collection.

Isolation of human umbilical cord blood mononuclear cells

Important: maintain the Ficoll-Paque and the cord blood samples at room temperature prior to and during the density gradient.

1. Dilute 1 volume of cord blood with 1 volume of PBS (1:1 dilution). For each 10 ml of diluted cord blood one gradient tube will be required.
2. Invert the Ficoll bottle several times to ensure thorough mixing.
3. Add 1 volume (i.e. 5 ml) of Ficoll-Paque in a 15 ml-centrifuge tube and carefully layer 2 volumes (i.e.: 10 ml) of the diluted cord blood sample. Do not mix the Ficoll with the diluted cord blood sample.
4. Centrifuge at 400xg for 30 minutes at 18-20 °C, **without braking**.
5. Draw off the upper layer using a pipette, leaving the Mononuclear Cell layer undisturbed at the interface.
6. Transfer the Mononuclear Cell layer of the gradients to one clean 50 ml centrifuge tube, using a pipette.
7. Add 3 volumes of PBS- to the volume of Mononuclear Cells. Suspend the cells by gently drawing, using a pipette.
8. Centrifuge at 400xg for 10 minutes at 18-20°C, and draw off the supernatant with pipette.
9. Repeat the cell washing procedure (steps 7 and 8).
10. Resuspend cells in 0.5ml of PBS- and place on melting ice.
Dilute 50 µl of cells in 450 µl of HBSS containing 0,04 % Trypan Blue and evaluate the percentage of viability immediately after making the suspension in a haemocytometer. Thereafter count the cells in the same way by using 50 µl of cells plus 450 µl of Turk solution.

Cryopreservation of huCBC

1. Prepare the freezing solution: 20 % DMSO and 40 % FBS in IMDM.
2. Adjust the cellular suspension to a concentration of 4×10^6 - 4×10^7 cell/ml in IMDM.
3. Dilute the cellular suspension 1:1 with the freezing solution to obtain a final concentration 2×10^6 - 2×10^7 cells/ml.
4. Fill the cryotubes with 1 ml of the cell suspension immediately after step 3 and place them at -80°C for 24 h in a "Mr. Frosty" container.
5. After 24 h, introduce the cryotubes in Liquid nitrogen.

Thawing of Hu-CBMNC

Note: All the procedures must be performed in rigorous sterile conditions operating in a Microbiological Safety Cabinet and using sterile reagents and materials.

1. Prepare 0.22 mm filtered solution I: 2.5% Human Serum Albumin and 5% Dextran 40 in IMDM (25mg HSA+50mg Dextran T 40/ml IMDM). (Prepare 1 volume of solution I per each volume of thawed cells).
2. Prepare 0.22 mm filtered solution II: FBS 10%, 3U DNase/ml in IMDM. (Prepare 8 volumes per each volume of thawed cells).
3. Rapidly thaw the required number of cryotubes in a waterbath at 37°C . Do not agitate the tubes.
4. Combine the contents of the cryotubes and dilute the thawed cell suspension 1:1 (Vol/Vol) with Solution I in 15 ml round bottom tube, mix gently by hand, and maintain at room temperature for 10 min.
5. Add 4 volumes of solution II per each volume of the suspension obtained in step 4, mix gently by hand, and maintain at room temperature for 10 minutes.
6. Filter with 100 mm Falcon cell strainer to remove clump on a tube 50 ml.
7. Centrifuge at 800xg for 10 min at 18 - 20°C , draw off the supernatant with pipette and resuspend the cells in 0.5 ml IMDM + 30% FBS. From now on put the cells in melting ice ($+4^\circ\text{C}$).
8. Dilute 50 ml of cells into 450 ml of HBSS containing 0.04% Trypan Blue (Sigma, Ref.T8154) and count the cells in a hemocytometer (e.g.: Bürker, Neubauer, etc.).
9. Adjust the suspension at 1.5×10^6 viable nucleated cells/ml (viability must be $>$ than 80%), then dilute the cell suspension to achieve the cell densities required by the experimental design (e.g. table 2).

Table 2: Example of cell dilution procedure for human mononuclear cord blood cells (hu-CBMNC). Starting cell suspension: 1.5×10^6 /ml.

			Dilution for preparing 1 ml of cell suspension	
Cell dilution	Tube	n°cells/dish (*)	Starting cells suspension (1.5×10^6 /ml)	IMDM + FBS 30%
A	CTRL 1	10,000	0.098 ml	0.902 ml
B	CTRL 3, D0@D8	75,000	0.733 ml	0.267 ml

(*) Cell density obtained if 0.3 ml of each dilution is added to the corresponding tube.

Test Material Exposure Procedures

The methylcellulose, the test article and the cells are mixed prior to plating the culture dishes.

1. Aliquots of test article, paired vehicle, and diluent should be stored as directed by the supplier.
2. On the night before the testing day, completely thaw aliquots of methylcellulose at $+4^\circ\text{C}$.
3. There are eleven tubes of cell culture mixture for each experiment: CTRL1, CTRL3 (LINEARITY CONTROL DISHES), D₀ (VEHICLE CONTROLS), and D₁- D₈ (DRUG CURVE). Each tube should contain 4.0 ml of methylcellulose culture medium.
4. On an incubator tray, label 35 mm Petri dishes according to the experimental design.
5. Prepare the drug and solvent stocks immediately prior to use according to the specific SOP.
6. Add 100 ml of IMDM to CTRL1 and CTRL3. Add 78 ml IMDM to each of D₀- D₈.

7. Prepare the toxicant dilutions in sterile 1.5 ml Eppendorf tube as described in **Table 3a-b** for Prescreening phase and **Table 4** for IC determination phase.
Using 2-200 µl certified pipettes with tips, add 22 µl of vehicle or 22 µl of each toxicant dilution to the methylcellulose tubes in melting ice. Vortex each tube 2x5 seconds. Final volume in each tube should be 4.1 µl after adding the toxicant.
8. Immediately add 0.3 ml of mouse or human MNC cell suspension, A or B, to each correspondent tube, move the tube gently to mix, and then vortex vigorously three times for 8 seconds.
9. Let the tubes stand for 5 minutes on melting ice to release air bubbles. Label the D₈ and D₄ dilution tube with toxicant name, dose level, date, and test location. Store these two tubes at -80°C for future analysis and record the stored samples on the Registration Form.
10. Distribute 1 ml of the cell-medium mixture into each of three Petri dishes using a 1 ml B-D insulin syringe with 19 Ga needle. Gently rotate the plate to spread the mixture evenly by allowing the meniscus to attach to the dish wall.
11. Incubate the cultures at 37°C in air + 5% CO₂ under saturated humidity for 7 days (murine assay) or 14 days (human assay).

Note: Sufficient humidity during incubation is critical because the drying of cultures drastically reduces colony formation. Saturated humidity can be achieved incubating six cultures dishes with one 60 mm dish (without lid) containing water inside a 150 mm Petri dish covered with a lid.

Table 3a:

Toxicant Dose Level (ECVAM Nomenclature)	Vehicle Stock (µl)	20 µg/ml Toxicant Stock or Prepared Dose Level (µl)	Total Volume of Working Solution (Toxicant+Vehicle) (µl)
D8	0	1.000	1.000
D7	800	200	1.000
D6	980	20	1.000
D5	990	10 of D7	1.000
D4	990	10 of D6	1.000
D3	990	10 of D5	1.000
D2	990	10 of D4	1.000
D1	990	10 of D3	1.000
D0	1.000	0	1.000

Table 3b:

Dilution of Toxicant into 200X Working Stock Solution	Concentration of Toxicant into 200X Working Stock Solution (mg/ml)	Volume of Working Solution to add to the Culture Dish (ml)	Final Fold-Dilution of Toxicant When added to the Culture Dish	Concentration of Toxicant When added to the Culture Dish (mg/ml)	Concentration of Vehicle added to the Culture Dish (Vol %)
1	20.000	22	200	100	0,5
5	4.000	22	1.000	20	0,5
50	400	22	10.000	2	0,5
500	40	22	100.000	0,2	0,5
5.000	4	22	1.000.000	0,02	0,5
50.000	0,4	22	10.000.000	0,002	0,5
500.000	0,04	22	100.000.000	0,0002	0,5
5.000.000	0,004	22	1.000.000.000	0,00002	0,5
--	0	22	N/a	0	0,5

Passing from screening phase to IC determination phase

From the CFU-GM results in the Screening Phase, identify the lowest dose level that completely inhibits CFU-GM and name it MTC. Identify the highest dose level that did *not* inhibit CFU-GM and name it HNTC. Calculate the log dose differential c between HNTC and MTC:

$$c = \log \{\text{final toxicant dilution @ HNTC}\} - \log \{\text{final toxicant dilution @ MTC}\}$$

To determine the concentrations to use in the Testing Phase (IC determination), assign the MTC to D8 and the HNTC to D2.

Divide c into six parts of log-size f ($= c: 6$) and assign these parts to the ECVAM dose level D3-D8, where D8 will equal the MTC. Make the following dilutions for CFU-GM testing.

Note that required volumes of toxicant stock may be smaller than can be pipetted.

These concentrations will require dilution of the drug stock before making a working stock (for example pipette 100 ml of a 1:100 dilution of toxicant stock, rather than 1 ml of undiluted toxicant stock). Remember to adjust the volume of added vehicle so that the final volume of toxicant plus vehicle is 1 ml.

Table 4: Calculation Table

Toxicant Dose Level (ECVAM Nomenclature)	Vehicle Stock (ml)	20 mg/ml Toxicant Stock or Prepared Dose Level (ml)	Total Volume of Working Solution to add to Cell Cultures (ml)	Volume of Working Solution to add to Cell Cultures (ml)	Concentration of Vehicle added to the Culture Dish (Vol %)
D8 (MTC)	V (= amount from Table 2.3)	T (= amount from Table 2.3)	1.000 (= $V+T$)	22	0,5
D7	$V + T(1-10^{-f})$	$10^{-f} T$	1.000	22	0,5
D6	$V + T(1-10^{-2f})$	$10^{-2f} T$	1.000	22	0,5
D5	$V + T(1-10^{-3f})$	$10^{-3f} T$	1.000	22	0,5
D4	$V + T(1-10^{-4f})$	$10^{-4f} T$	1.000	22	0,5
D3	$V + T(1-10^{-5f})$	$10^{-5f} T$	1.000	22	0,5

D2	$V + T(1-10^{-6f})$ (= amount from Table 2.3)	$10^{-6f} T$ (= amount from Table 2.3)	1.000	22	0,5
D1	$V + T(1-10^{-7f})$	$10^{-7f} T$	1.000	22	0,5
D0	1.000	0	1.000	22	0,5

Table 5: Calculation table

Toxicant Dose Level (ECVAM Nomenclature)	Vehicle Stock (ml)	20 mg/ml Toxicant Stock or Prepared Dose Level (ml)	Total Volume of Working Solution to add to Cell Cultures (ml)	Volume of Working Solution to add to Cell Cultures (ml)	Concentration of Vehicle added to the Culture Dish (Vol %)
D8			1.000	22	0,5
D7			1.000	22	0,5
D6			1.000	22	0,5
D5			1.000	22	0,5
D4			1.000	22	0,5
D3			1.000	22	0,5
D2			1.000	22	0,5
D1			1.000	22	0,5
D0			1.000	22	0,5

From CFU-GM results in the Screening Phase:

- Dx completely inhibited CFU-GM, so it is the MTC
- Dy did *not* inhibit CFU-GM but D3 did, so D2 is the HNTC
- Log dose differential c between HNTC and MTC is

$$c = \log\{\text{final toxicant dilution@HNTC}\} - \log\{\text{final toxicant dilution@MTC}\}$$

$$= \log\{y\} - \{x\}$$

Example 1

From CFU-GM results in the Screening Phase:

- D7 completely inhibited CFU-GM, so it is the MTC
- D2 did *not* inhibit CFU-GM but D3 did, so D2 is the HNTC
- Log dose differential c between HNTC and MTC is

$$c = \log\{\text{final toxicant dilution @ HNTC}\} - \log\{\text{final toxicant dilution @ MTC}\}$$

$$= \log\{100.000.000\} - \{1.000\}$$

$$= 8 - 3 = 5$$

- So concentration interval divided into six equal parts of
log-size f ($= c: 6$) = $5/6$

Toxicant Dose Level (ECVAM Nomenclature)	Vehicle Stock (ml)	20 mg/ml Toxicant Stock or Prepared Dose Level (ml)	Total Volume of Working Solution (Toxicant +Vehicle) (ml)	Volume of Working Solution to add to Cell Cultures (ml)	Concentration of Vehicle added to the Culture Dish (Vol %)
D8 (=MTC, D7 from Screening Phase)	800	200	1.000	22	0,5
D7	971	29	1.000	22	0,5
D6	995,7	4.3	1.000	22	0,5
D5	937 (instead of 999,37)	63 of 1:100 diluted stock (instead of 0,63)	1.000	22	0,5
D4	990,7 (instead of 999,907)	9.3 of 1:100 diluted stock (instead of 0,093)	1.000	22	0,5
D3	860 (instead of 999,986)	140 of 1:10.000 diluted stock (instead of 0,014)	1.000	22	0,5
D2	980 (instead of 999,998)	20 of 1:10.000 diluted stock (instead of 0,0020)	1.000	22	0,5
D1	970 (instead of 999,99999)	30 of 1:100.000 of diluted stock (instead of 0,0003)	1.000	22	0,5
D0	1.000	0	1.000	22	0,5

Example 2

From CFU-GM results in the Screening Phase:

- D5 completely inhibited CFU-GM, so it is the MTC
- D4 did *not* inhibit CFU-GM, did, so it is the HNTC
- Log dose differential c between HNTC and MTC is

$$c = \log \{ \text{final toxicant dilution @ HNTC} \} - \log \{ \text{final toxicant dilution @ MTC} \} = \log \{ 1.000.000 \} - \log \{ 100.000 \} = 6 - 5 = 1$$

- So concentration interval divided into six equal parts of log-size f
(= c: 6) = 1/6

Toxicant Dose Level (ECVAM Nomenclature)	Vehicle Stock (ml)	20 mg/ml Toxicant Stock or Prepared Dose Level (ml)	Total Volume of Working Solution (Toxicant + Vehicle) (ml)	Volume of Working Solution to add to Cell Cultures (ml)	Concentration of Vehicle added to the Culture Dish (Vol %)
D8 (=MTC, D5 from Screening Phase)	990	10 of 1:5 diluted stock (200 diluted with 800 –see Screening Phase)	1.000	22	0,5
D7	993,2	6,8 of 1:5 diluted stock	1.000	22	0,5
D6	995,4	4,6 of 1:5 diluted stock	1.000	22	0,5
D5	936 (instead of 996,8)	64 of 1:100 diluted stock (instead of 3,2 of 1:5 diluted stock)	1.000	22	0,5
D4	956 (instead of 997,8)	44 of 1:100 diluted stock (instead of 2,2 of 1:5 diluted stock)	1.000	22	0,5
D3	970 (instead of 998,5)	30 of 1:100 diluted stock (instead of 1,5 of 1:5 diluted stock)	1.000	22	0,5
D2 (HNTC)	980 (instead of 999)	20 of 1:100 diluted stock (instead of 1,0 of 1:5 diluted stock)	1.000	22	0,5
D1	986 (instead of 999,32)	14 of 1:100 diluted stock (instead of 0,68 of 1:5 diluted stock)	1.000	22	0,5
D0	1.000	0	1.000	22	0,5

Endpoint Measurement

Scoring the colonies

Colonies are counted after 7 days (murine cells) or 14 days (human cells) of incubation as follows:

1. Place the culture dish inside a 60 mm gridded tissue culture dish.
2. CFU-GM colonies are scored by scanning the whole Petri dish by using an inverted microscope (about 20 - 25 X magnification). It is critical to use 20 - 25X magnification; DO NOT USE 40X magnification !! A D₈ plate should be scored first to determine what is the minimal acceptable aggregate considered as a colony. In this highest drug level, the colonies will be the smallest and most difficult to define because of toxicity. After scoring one D₈ replicate, randomly count one replicate from the other experimental groups. Then score a second D₈ replicate, and then randomly

score the second replicate from the remaining groups. Repeat this sequence for the third replicates.

3. Aggregates containing 50 or more cells are defined as CFU-GM colonies.
4. Aggregates with 20-50 cells are defined as clusters.

Note: For correct discrimination between colonies and clusters, carefully evaluate the number of cells for each aggregate! It is important to look carefully at the edge of the plate. It is a place where a lot of colonies grow when a high cellular density is seeded.

Criteria for colony counting

Note: Applies to colony morphology at 20 - 25X magnification; DO NOT USE 40X

1. **Compact colonies:** with a central dense nucleus and a peripheral halo. These colonies are very easy to score.
2. **Diffuse and spread colonies:** Without apparent nucleus. Care must be taken with the magnification, since an excessive one (> 30X) can lead to lose this kind of colonies.
With high densities of colonies in the plate (> 150 colonies/plate) it is really hard (sometimes impossible) to score these colonies.
This is one of the reasons for suggesting not to score very high number of colonies (although correlations could be good, the scoring is really hard).
3. **Multicentric colonies:** are found frequently in Medium B but it is unusual to find them in Medium A. These are colonies with two or more dense nucleus nearby, with a common peripheral halo growing at the same depth in the plate.
They should be considered as one colony.
4. **Burst-forming units (BFUs):** Multifocal colonies: are aggregates of several colonies or clusters, with or without a peripheral halo. These must be counted as one colony.

Table 6: Experimental Design (Module to perform 1 prescreening + 2IC Determination on 3 drugs).

Experiment	Drug	Doses (in triplicate)	Linearity control (*)	Total tubes	Total dishes
Prescreening	A	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
	B	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
	C	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
IC Determination 1	A	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
	B	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
	C	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
IC Determination 2	A	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
	B	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6
	C	D0;D1;D2;D3;D4;D5;D6;D7;D8	Ctrl 1; Ctrl 3	11	27+6

Table 6 Legend:

A-B-C: correspond to three codified drugs.

D0= Solvent (without drug) at higher concentration used in the drug dilution (3 dishes).

D1-D8= 1:10 serial dilution (3 dishes/dose) in the presence of 40.000 cells/dish (murine bone marrow cells) or 75000 cells/dish (human cord blood cells). The doses for prescreening phase and IC determination phase 1 and 2 were calculated according to the procedure reported in section 2.4).

(*): No drug, no solvent, only cells in culture medium.

Murine bone marrow cells: ctrl 1= 2,500 cells/dish, ctrl 3= 40,000 cells/dish.

Human cord blood cells: ctrl 1= 10,000 cells/dish, ctrl 3= 75,000 cells/dish.

Fig 1: Compact colony; cell density: 10000 cells/dish; murine medium A; colonies: 1.




Fig 2: Diffuse colony; cell density: 10000 cells/dish; murine medium A; colonies: 1.




Fig 3: Multicentric colony; cell density: 80000 cells/dish; murine medium B; colonies: 1.




Fig 4: Burst-forming unit or multifocal colony; cell density: 80000 cells/dish; murine medium B; colonies: 1.





Fig 5: Compact colony (under) and Diffuse/spread colony (upper); cell density: 80000 cells/dish; murine medium B; colonies: 2.



Prediction Model

For the purpose of the ECVAM's study "*In Vitro* tests for haematotoxicity: prevalidation and validation of Colony Forming Unit Granulocyte/Macrophage (CFU-GM) assays for predicting acute neutropenia" (1997 – 2000) the IC₉₀ (90% inhibitory concentration values) determined for each drug in human and murine were used to predict a human Maximum Tolerated Dose (MTD). Accurate prediction is defined as the prediction of human MTD that lies with 4-fold of the actual human value.

Example (from Pessina et al., 2000):

Xenobiotic	IC ₉₀ ratio (Human: murine)	Murine MTD (mg/m ² /cycle)	Predicted Human MTD	Actual Human MTD (mg/m ² /cycle)	Successful Prediction (Yes/No)
Flavopiridol	0.41	100	41	50*	yes

*Maximum value must be: (41 x 4)

Bibliography

- Anon (2000)
Draft Final report of the stage II, Validation Phase, of the "In vitro tests for haematotoxicity: prevalidation and validation of Colony Forming Unit-Granulocyte/Macrophage (CFU-GM) assays for predicting acute neutropenia",
Consorzio Milano Ricerche
- Anon (1998)
Final report of the stage I of the "In vitro tests for haematotoxicity: prevalidation and validation of Colony Forming Unit-Granulocyte/Macrophage (CFU-GM) assays for predicting acute neutropenia",
Consorzio Milano Ricerche
- Balls M. and Karcher W. (1995)
The validation of alternative methods.
Alternatives to Laboratory Animals (ATLA) 23, 884-886
- Balls M., Blaauboer B.J., Fentem J.H., Bruner L., Combes R.D., Ekwall B., Fielder R.J., Guillouzo A., Lewis R.W., Lovell D.P., Reinhardt C.A., Repetto G., Sladowski D., Spielmann H. and Zucco F. (1995)
Practical aspects of the validation of toxicity test procedures. The report and recommendations of ECVAM workshop 5.
Alternatives to Laboratory Animals (ATLA) 23, 129-147
- Cerrato L, Valeri A, Bueren JA, et al. (2009)
In vitro sensitivity of granulo-monocytic progenitors as a new toxicological cell system and endpoint in the ACuteTox Project.
Toxicology and Applied Pharmacology 238, 111-9
- Curren R.D., Southee J.A., Spielmann H., Liebsch M., Fentem J.H. and Balls M. (1995)
The role of prevalidation in the development, validation and acceptance of alternative methods.ECVAM Prevalidation Task Force Report 1.
Alternatives to Laboratory Animals (ATLA) 23, 211-217
- Deldar, A., Parchment, R.E. (1997)
Preclinical Risk Assessment for Hematotoxicity: Animal Models and In Vitro Systems.
Comprehensive Toxicology 4, 303-320
- Du, D.L., Volpe, D.A. & Murphy, M.J. (1989)
Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells.
International Journal of Cell Cloning 7, 303-313
- ESAC (2006)
Statement on the application of the CFU-GM assay for predicting acute neutropenia in humans, 24th meeting of ECVAM Scientific Advisory Committee (ESAC), 20-21 March 2006. European Commission - Joint Research Centre, Institute for Health and Consumer Protection, European Centre for Validation of Alternative Methods (ECVAM).
[*ECVAM Scientific Advisory Committee.*](#)
- EU (2008)
Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures (CLP). Entered into force on the 20 January 2009 which will stepwise replace the Council Directive 67/548/EEC (substances), Directive 1999/45/EC (preparations), amending Regulation (EC) No 1907/2006 and subsequent amendments and adaptations. [Link to document](#) (last access 27.03.2013)
Official Journal of the European Communities L 353, 1-1355
- Erickson-Miller C.L., May R., Tomaszewski J., Osborn B., Murphy M.J.Jr., Page J.G. and Parchment R.E. (1997)
Differential Toxicity of Campothecin, Topotecan and 9-Aminocamptothecin to Human, canine and Murine Myeloid Progenitors (CFU-GM) *In Vitro*.
Cancer Chemotherapy and Pharmacology 39, 467-472
- Ghielmini M., Bosshard G., Capolongo L., Geroni M.C., Pesenti E., Torri V., D'Incalci M., Cavalli F. and Sessa C. (1997)
Estimation of haematological toxicity of minor groove alkylators using tests on human cord blood cells.
British Journal of Cancer 75 (6), 878-883
- Gribaldo L., Bueren J., Deldar A., Okland P., Meredith C., Moneta D., Mosesso P., Parchment R., Parent-Massin D., Pessina A., San Roman J. and Schoeters G. (1996)
The use of in vitro systems for Evaluating Haematotoxicity. The report and recommendations of ECVAM

workshop 14.

Alternatives to Laboratory Animals (ATLA) 24, 211-231

- Lewis, I.D., Rawling, T., Dyson, P.G., Haylock, D.N., Juttner, D.N. & To, L.B. (1996)
Standardization of the CFU-GM assay using hematopoietic growth factors.
Journal Hematometer., 625-630
- Metcalf, D. (1980)
Clonal analysis of proliferation and differentiation of paired daughter cells: action of granulocyte-macrophage colony stimulating factors on granulo-macrophage precursors.
Proceedings of the National Academy of Sciences of the United States of America 77, 5327-5330
- Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D. and Ghielmini M. (1998)
Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests.
Annals of Oncology 9 (4), 357-364
- Parchment R.E., Volpe D.A., LoRusso P.M., Erickson-Miller C.L., Murphy M.J. Jr. and Grieshaber C.K. (1994)
In vivo- in vitro correlation of myelotoxicity of 9-methoxyprazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine and canine marrow.
Journal of the National Cancer Institute 86, 273-280
- Parchment, R.E. (1998)
Alternative Testing Systems for Evaluating Non-Carcinogenic, Haematologic Toxicity.
Environmental Health Perspectives Supplements; Alternative Testing Methodologies, Human Health Effects on Dioxins and Furans 106, Suppl. 2, 541-557
- Parchment, R.E., Huang, M., Erickson-Miller, C.L. (1993)
Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning.
Toxicologic Pathology 21(2), 241-250
- Parchment, R.E., Murphy, M.J. Jr. (1997)
Human Hematopoietic Stem Cells: Laboratory Assessment and Response to Toxic Injury.
Comprehensive Toxicology 4, 335-361
- Parent-Massin, D. and Parchment R.E. (1998)
Haematotoxicity of mycotoxins.
Revue de Medecine Veterinaire 149, Issue 6, 591-598
- Pessina A. (1998)
The Granulocyte Macrophage Colony-Forming Unit Assay.
Animal Cell Culture Techniques, 217-230
- Pessina A., Albella B., Bayo M., Brantom P., Casati S., Croera C., Parchment R., Parent-Massin D., Schoeters G., Sibiri Y., Van Den Heuvel R., and Gribaldo L. (2002)
In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay.
Alternatives to Laboratory Animals (ATLA) 30(Suppl 2), 75-79
- Pessina A., Albella B., Bueren J., Brantom P., Casati S., Corrao G., Gribaldo L., Parchment R., Parent-Massin D., Piccirillo M., Rio B., Sacchi S., Schoeters G. and van den Heuvel R. (2000)
Method development for a prevalidation study of in vitro GM-CFU assay for predicting myelotoxicity.
Progress in the Reduction, Refinement and Replacement of Animal Experimentation 31 A, 679-691
- Pessina A., Bonomi A., Baglio C., Cavicchini L., and Gribaldo L. (2009)
Refinement and optimization of the rat CFU-GM assay to incorporate the use of cryopreserved bone-marrow cells for in vitro toxicology applications.
Alternatives to Laboratory Animals (ATLA) 37, 417-425
- Pessina A., Bonomi A., Cavicchini L., Albella B., Cerrato L., Parent-Massin D., Sibiri Y., Parchment R., Behrsing H., Verderio P., Pizzamiglio S., Giangreco M., Baglio C., Cocce V., Sisto F., and Gribaldo L. (2010)
Prevalidation of the rat CFU-GM assay for in vitro toxicology applications.
Alternatives to Laboratory Animals (ATLA) 38, 105-117
- Pessina A., Croera C., Bayo M., Malerba I., Passardi L., Cavicchini L., Neri M.G., and Gribaldo L. (2004)
A methylcellulose microculture assay for the in vitro assessment of drug toxicity on granulocyte/macrophage progenitors (CFU-GM).
Alternatives to Laboratory Animals (ATLA) 32, 17-23
- Pessina A., Parent-Massin D., Albella B., Van Den Heuvel R., Casati S., Croera C., Malerba I., Sibiri Y., Gomez S., de Smedt A., and Gribaldo L. (2009)

Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs.

Toxicology In Vitro 23, 194-200

- Pessina, A., Albella, B., Bayo, B., Bueren, J., Brantom, P., Casati, S., Croera, Gagliardi, G., Foti, P., Parchment, R., Parent-Massin, D., Schoeters, G., Sibiril, Y., Van den Heuvel, R., Gribaldo, L. (2003)
Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.
Toxicological Sciences 75, 355-367
- Pessina, A., Albella, B., Bueren, J., Brantom, P., Casati, S., Gribaldo, L., Croera, C., Gagliardi, G., Foti, P., Parchment, R., Parent-Massin, D., Sibiril, Y., Schoeters, G., Van den Heuvel, R. (2001)
Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.
Toxicology In Vitro, 729-740
- Pessina, A.; Bonomi, A. (2010)
Prediction of potential drug myelotoxicity by *in vitro* assays on haematopoietic progenitors.
Methods in Bioengineering: Alternative technologies to animal testing., 115-131
- Pessina, A.; Bonomi, A. (2007)
CFU-GM assay for evaluation of drug Myelotoxic Activity.
Current Protocols in Toxicology 34:20.2.1-20.2.18
- Prieto, P., Kinsner-Ovaskainen, A., Stanzel, S., Albella, B., Artursson, P., Campillo, N., Cecchelli, R., Cerrato, L., Díaz, L., Di Consiglio, E., et al. (2013)
The value of selected *in vitro* and *in silico* methods to predict acute oral toxicity in a regulatory context: Results from the European Project ACuteTox.
Toxicology In Vitro 27(4), 1357-1376